Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 0/6 |
Dividends | 0/6 |
Aequus Pharmaceuticals Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | CA$0.025 |
52 Week High | CA$0.06 |
52 Week Low | CA$0.01 |
Beta | 0.17 |
1 Month Change | 66.67% |
3 Month Change | 150.00% |
1 Year Change | -37.50% |
3 Year Change | -82.14% |
5 Year Change | -82.76% |
Change since IPO | -96.43% |
Recent News & Updates
Shareholder Returns
AQS | CA Pharmaceuticals | CA Market | |
---|---|---|---|
7D | 0% | -0.8% | -0.5% |
1Y | -37.5% | 46.7% | 11.9% |
Return vs Industry: AQS underperformed the Canadian Pharmaceuticals industry which returned 46.7% over the past year.
Return vs Market: AQS underperformed the Canadian Market which returned 11.9% over the past year.
Price Volatility
AQS volatility | |
---|---|
AQS Average Weekly Movement | 67.8% |
Pharmaceuticals Industry Average Movement | 14.2% |
Market Average Movement | 8.7% |
10% most volatile stocks in CA Market | 17.5% |
10% least volatile stocks in CA Market | 3.0% |
Stable Share Price: AQS's share price has been volatile over the past 3 months.
Volatility Over Time: AQS's weekly volatility has increased from 43% to 68% over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2013 | 12 | Doug Janzen | www.aequuspharma.ca |
Aequus Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. The company markets ZIMED PF, a preservative-free bimatoprost ophthalmic solution. It also develops a range of prescription-free dry eye products under the OPTASE name; and REV-0100 for the treatment of stargardt disease.
Aequus Pharmaceuticals Inc. Fundamentals Summary
AQS fundamental statistics | |
---|---|
Market cap | CA$3.32m |
Earnings (TTM) | -CA$2.88m |
Revenue (TTM) | CA$215.20k |
15.4x
P/S Ratio-1.2x
P/E RatioIs AQS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
AQS income statement (TTM) | |
---|---|
Revenue | CA$215.20k |
Cost of Revenue | CA$89.83k |
Gross Profit | CA$125.37k |
Other Expenses | CA$3.01m |
Earnings | -CA$2.88m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -0.022 |
Gross Margin | 58.26% |
Net Profit Margin | -1,339.45% |
Debt/Equity Ratio | -101.2% |
How did AQS perform over the long term?
See historical performance and comparison